SETD2 and miR-21 as therapeutic targets for NUT midline carcinoma

Nana Yoshida(Asahikawa Medical University), Yoshinobu Ohsaki(Asahikawa Medical College Hospital)

Research Square

March 16, 2021

10.21203/rs.3.rs-286917/v1

Cited by 0

Related Papers

Activation of Src signaling mediates acquired resistance to ALK inhibition in lung cancer

|International Journal of Oncology|2017|34

The feasibility of circulating tumor DNA analysis as a marker of recurrence in triple-negative breast cancer

|Oncology Letters|2021|7